Skip to main content
. 2021 Jan 22;7(4):eabe7174. doi: 10.1126/sciadv.abe7174

Fig. 5. Anticancer activity of NV-ZIF in PBMCs isolated from AML patient samples.

Fig. 5

(A) Quantitative analysis of CD8+ IFN-γ+ and CD8+ TNF-α+ T cells in serum in response to various treatments after 6 and 12 hours. Error bars are based on SE (n = 5). (B) Representative flow cytometry plots of lymphocytes of AML treated with NV-ZIF. Statistical significance was calculated by one- or two-way ANOVA and Tukey’s multiple comparisons test: *P < 0.05.